IP Library Granted Patent US 10,829,550
Granted Patent B2
US 10,829,550 · App. 15/953,139 · Granted Nov 10, 2020

Polynucleotides encoding anti-CXCL13 antibodies

Inventors: Ekaterina Klimatcheva (Webster, NY); Mark Paris (Mendon, NY); Ernest S. Smith (W. Henrietta, NY)
Assignee: Vaccinex, Inc.
C07K16/24A61K2039/505C07K2317/24C07K2317/33C07K2317/34C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,550
App. No.
15/953,139
Granted
Nov 10, 2020
Kind
B2
Abstract

Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.

Claims (20)

1. An isolated polynucleotide comprising a nucleic acid which encodes a VH polypeptide comprising the three complementarity determining regions HCDR1, HCDR2, and HCDR3 of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively, wherein an antibody or antigen binding fragment thereof comprising the VH polypeptide and a VL polypeptide comprising the three complementarity determining regions LCDR1, LCDR2, and LCDR3 of SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11, respectively, or the LCDR1, LCDR2, and LCDR3 of SEQ ID NO: 16, SEQ ID NO: 10, and SEQ ID NO: 11, respectively specifically binds to human, murine, and cynomolgus monkey CXCL13.

2. The polynucleotide of claim 1 , wherein the VH polypeptide comprises an amino acid sequence at least 90% identical to SEQ ID NO: 13 or SEQ ID NO: 3.

3. The polynucleotide of claim 2 , wherein the VH polypeptide comprises the amino acid sequence SEQ ID NO: 13 or SEQ ID NO: 3.

4. An isolated polynucleotide comprising a nucleic acid which encodes a VL polypeptide comprising the three complementarity determining regions LCDR1, LCDR2, and LCDR3 of SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11, respectively, or the LCDR1, LCDR2, and LCDR3 of SEQ ID NO: 16, SEQ ID NO: 10, and SEQ ID NO: 11, respectively, wherein an antibody or antigen binding fragment thereof comprising the VL polypeptide and a VH polypeptide comprising the three complementarity determining regions HCDR1, HCDR2, and HCDR3 of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively specifically binds to human, murine, and cynomolgus monkey CXCL13.

5. The polynucleotide of claim 4 , wherein the VL polypeptide comprises an amino acid sequence at least 90% identical to SEQ ID NO: 8, SEQ ID NO: 17, or SEQ ID NO: 15.

6. The polynucleotide of claim 5 , wherein the VH polypeptide comprises the amino acid sequence SEQ ID NO: 8, SEQ ID NO: 17, or SEQ ID NO: 15.

7. A composition comprising an isolated polynucleotide comprising a nucleic acid that encodes a VH polypeptide and an isolated polynucleotide comprising a nucleic acid that encodes a VL polypeptide, wherein the VH polypeptide comprises the HCDR1, HCDR2, and HCDR3 of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively, and wherein the VL polypeptide comprises the LCDR1, LCDR2, and LCDR3 of SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11, respectively, or the LCDR1, LCDR2, and LCDR3 of SEQ ID NO: 16, SEQ ID NO: 10, and SEQ ID NO: 11, respectively, and wherein an antibody or antigen binding fragment thereof comprising the VH polypeptide and the VL polypeptide specifically binds to human, murine, and cynomolgus monkey CXCL13.

8. The composition of claim 7 , wherein the VH polypeptide and the VL polypeptide are at least 90% identical to the VH and VL amino acid sequences:

(a) SEQ ID NO: 3 and SEQ ID NO: 8, respectively;

(b) SEQ ID NO: 13 and SEQ ID NO: 15, respectively; or

(c) SEQ ID NO: 13 and SEQ ID NO: 17, respectively.

9. The composition of claim 8 , wherein said VH polypeptide and the VL polypeptide comprise the amino acid sequences:

(a) SEQ ID NO: 3 and SEQ ID NO: 8, respectively;

(b) SEQ ID NO: 13 and SEQ ID NO: 15, respectively; or

(c) SEQ ID NO: 13 and SEQ ID NO: 17, respectively.

10. The composition of claim 7 wherein the VH encoding polynucleotide and the VL encoding polynucleotide are contained on a single vector.

11. The composition of claim 7 wherein the VH encoding polynucleotide is contained on a first vector and the VL encoding polynucleotide is contained on a second vector which is non-identical to said first vector.

12. A vector according to claim 10 .

13. A host cell comprising the vector 12.

14. A method of producing an antibody or fragment thereof which specifically binds CXCL13, comprising culturing the host cell of claim 13 , and recovering said antibody, or fragment thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2023
From: VACCINEX, INC.
To: 3I, L.P.
Reel/Frame 062308/0405 →
SECURITY INTEREST Recorded Aug 10, 2020
From: VACCINEX, INC.
To: 3I, L.P.
Reel/Frame 053440/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2018
From: KLIMATCHEVA, EKATERINA; PARIS, MARK; SMITH, ERNEST S.
To: VACCINEX, INC.
Reel/Frame 045547/0136 →
Continuity (4)
Division 13820278
Provisional Application 61481645 · May 2, 2011
Provisional Application 61379672 · Sep 2, 2010
Related Publication 20180244764A1 · Aug 30, 2018